Antimicrobial resistance in the hospital setting: Impact, trends, and infection control measures

Pharmacotherapy

Volumn 25, Issue 10 II, 2005, Pages

  Stein, Gary E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Antimicrobial resistance; Bacterial pathogens; Infection control

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFEPIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOLIC ACID ANTAGONIST; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; LINCOSAMIDE; MACROLIDE; METICILLIN; PIPERACILLIN; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; TIMENTIN; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AWARENESS; DRUG SURVEILLANCE PROGRAM; DRUG USE; ENTEROCOCCUS; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-INFECTIVE AGENTS; BACTEREMIA; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; INFECTION CONTROL;

EID: 26044474474     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.10part2.44S     Document Type: Review

References (31)

1. Shlaes DM, Gerdling DN, John JF, et al. Society for Healthcare Epidemiology of America and Infectious Disease Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584-99.
2. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003;36(suppl 1):S11-23.
3. World Health Organization. Overcoming antimicrobial resistance: world health report on infectious diseases 2000. Available from http://www.who.int/ infectious-disease-report/2000/other_version/index-rpt2000_text.html. Accessed May 18, 2005.
4. Boyce JM, Pittet D. Guidelines for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practice and Advisory Committee and the HICPAC/ SHEA/APIC/IDSA Hand Hygiene Task Force. Am J Infect Control 2002;30(8):1-46.
5. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in U.S. hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:307-17.
6. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005;40:562-73.
7. Jones ME, Draghi DC, Thornsberry C, et al. Emerging resistance among bacterial pathogens in the intensive care unit: a European and North American surveillance study (2000-2002) [online exclusive article]. Ann Clin Microbiol Antimicrob 2004;3: 14. Available from http://www.ann-clinmicrob.com/content/3/1/ 14.
8. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
9. Rybak MJ, LaPlante KL. Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy 2005;25:74-85.
10. Nathisuwan S, Burgess DS, Lewis JS II. Extended-spectrum β-lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001;21:920-8.
11. Bradford PA. What's new in β-lactamases? Curr Infect Dis Rep 2001;3:13-19.
12. Lautenbach E, Strom BL, Bilker WB, et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001;35:1288-94.
13. Colodner R. Extended-spectrum β-lactamases: a challenge for clinical microbiologists and infection control specialists. Am J Infect Control 2005;33:104-7.
14. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States. Am J Med 2005;118;259-68.
15. Wenzel RP, Edmond MB. The impact of hospital-acquired bloodstream infections. Emer Infect Dis 2001;7:174-7.
16. Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003;47:3222-32.
17. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother 2005;49:118-25.
18. Flamm RK, Weaver MR, Thornsberry ME, et al. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother 2004;48:2431-6.
19. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004; 48:4606-10.
20. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-acquired, and healthcare-acquired pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
21. Masterton RG. Antibiotic cycling: more than it might seem? J Antimicrob Chemother 2005;55:1-5.
22. Bantar C, Vesco E, Heft C, et al. Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance. Antimicrob Agents Chemother 2004;48:392-5.
23. Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST surveillance program (1998-2002). Clin Infect Dis 2003;36:963-70.
24. Pletz MW, McGee L, Jorgensen J, et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004;48:3491-7.
25. Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med 2004;117(suppl 3A):S3-15.
26. Aspa J, Rojas O, Rodriguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004;38:787-98.
27. Gold HS. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 2001;33:210-19.
28. Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002;46:1619-28.
29. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710-21.
30. Rice LB, Hutton-Thomas R, Lakticova V, et al. β-Lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci. J Infect Dis 2004;189:1113-18.
31. Bhalla A, Pultz NJ, Ray AJ, et al. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect Control Hosp Epidemiol 2003;24:644-9.